Celldex Therapeutics CLDX
NASDAQ CLDX
$30.31 -0.34 (-1.11%)
As of: Nov 11, 2026 · 3:09 PM EST

Celldex Therapeutics (CLDX) Return on Sales [ROS] (2009 - 2026)

Updated

Celldex Therapeutics (CLDX) recorded Return on Sales [ROS] of -366468.18% in Q2 2026, down 357720.65 percentage points from -8747.53% a year earlier but up 196431.82 percentage points from the prior quarter.

Analysis

Celldex Therapeutics (CLDX) Return on Sales [ROS] (2009 - 2026) Analysis & Trends

On a TTM basis, Celldex Therapeutics' Return on Sales [ROS] came in at -206220.25% as of Jun 30, 2026, down 202166.57 percentage points year-over-year; for FY2025, it was -18599.81%, down 15820.92 percentage points from FY2024.

  • Annual Return on Sales [ROS] has a five-year change of -17745.75 percentage points (FY2020 to FY2025).
  • Across earlier years, Return on Sales [ROS] came in at -2778.89% in FY2024 (-533.62 pp), -2245.27% in FY2023 (+2643.74 pp), -4889.01% in FY2022 (-3357.23 pp) and -1531.78% in FY2021 (-677.72 pp).
  • Quarterly Return on Sales [ROS] has ranged from -562900.00% in Q1 2026 to -1152.92% in Q4 2023 over the past five years.
  • On a year-over-year basis, Return on Sales [ROS] has declined for five consecutive quarters, with an average year-over-year change of -122436.82 percentage points over the last eight quarters.
  • Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 17003.57 percentage points in Q1 2025, against a drop of 553872.81 percentage points in Q1 2026 at the low end.
  • Per Business Quant, the preceding three quarters came in at -562900.00% (Q1 2026), -72027.27% (Q4 2025) and -9855.38% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Celldex Therapeutics 2.41 Bn 69.14 Mn - -211,684.81%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -211,684.81%
Jun 30, 2026 -366,468.18%
Mar 31, 2026 -562,900.00%
Dec 31, 2025 -72,027.27%
Sep 30, 2025 -9,855.38%
Jun 30, 2025 -8,747.53%
Mar 31, 2025 -9,027.19%
Dec 31, 2024 -4,768.26%
Sep 30, 2024 -1,633.53%
Jun 30, 2024 -1,854.16%
Mar 31, 2024 -26,030.77%
Dec 31, 2023 -1,152.92%
Sep 30, 2023 -2,718.46%
Jun 30, 2023 -12,389.93%
Mar 31, 2023 -3,357.91%
Dec 31, 2022 -1,728.77%
Sep 30, 2022 -6,804.91%
Jun 30, 2022 -22,328.83%
Mar 31, 2022 -13,366.09%
Dec 31, 2021 -6,089.82%
API Access

Celldex Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CLDX&period=max&api_key=YOUR_API_KEY